V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260009741 | 260006228 | 1.6 | 60.1 | Palliative (P) | 2015-06-15 | 2015-06-22 | Cisplatin + Radiotherapy | N | N | 260009128 | METHOTREXATE INTRATHECAL |
| 260009742 | 260006228 | 1.74 | 109.9 | Curative (C) | 2016-10-19 | 2016-10-21 | Cisplatin + Etoposide (3 day) | 99 | null | 260009128 | BENDAMUSTINE |
| 260009743 | 260006229 | 1.7 | 80.7 | Curative (C) | 2016-09-04 | 2016-09-05 | Cisplatin + Pemetrexed | N | N | 260009217 | NOT MATCHED |
| 260009744 | 260006229 | null | 85.4 | Curative (C) | 2015-08-07 | 2015-08-08 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 2 | N | 260009217 | GEMCARBO |
| 260009745 | 260006230 | 1.64 | 52.1 | Curative (C) | 2018-02-19 | 2018-02-25 | CARBOPLATIN + PACLITAXEL | 2 | N | 260009294 | RITUXIMAB |
| 260009746 | 260006230 | null | 91 | Palliative (P) | 2014-06-26 | 2014-07-22 | ETOPOSIDE | N | N | 260009294 | POMB |
| 260009747 | 260006231 | 1.65 | 81.7 | Palliative (P) | 2015-08-15 | 2015-08-28 | Cisplatin + Etoposide (5 day) | 02 | N | 260009325 | EP |
| 260009748 | 260012360 | null | null | Not known (9) | 2015-12-16 | 2016-02-06 | BENDAMUSTINE | N | N | 260009326 | RITUXIMAB |
| 260009749 | 260006232 | 1.57 | null | Palliative (P) | null | 2015-06-15 | Rituximab | N | N | 260009334 | CHOP |
| 260009750 | 260006233 | 1.83 | null | Curative (C) | 2018-03-17 | 2018-03-24 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 260009359 | CISPLATIN + ETOPOSIDE |
| 260009751 | 260006234 | null | 53.1 | Curative (C) | null | 2016-05-23 | CISPLATIN + ETOPOSIDE | N | null | 260009419 | EP |
| 260009752 | 260006234 | 1.83 | 75 | Not known (9) | 2018-11-12 | 2018-11-16 | Rituximab | N | null | 260009419 | CISPLATIN + ETOPOSIDE |
| 260009753 | 260006235 | null | 137 | Palliative (P) | 2013-10-04 | 2013-10-11 | Cisplatin + Vinorelbine (IV) | N | N | 260009456 | CISPLATIN + ETOPOSIDE |
| 260009754 | 260006235 | null | 92 | Curative (C) | 2017-02-18 | 2017-02-21 | EP | 99 | null | 260009456 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |
| 260009755 | 260015691 | 1.75 | 73 | Palliative (P) | 2017-04-26 | 2017-04-26 | TIP | N | N | 260009510 | TRIAL |
| 260009756 | 260006236 | 1.56 | null | Curative (C) | 2014-10-26 | 2014-10-26 | Rituximab | 2 | N | 260009531 | CISPLATIN + RT |
| 260009757 | 260006236 | 1.77 | null | Disease modification (D) | 2016-04-28 | 2016-04-30 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 01 | N | 260009531 | CISPLATIN + ETOPOSIDE |
| 260009758 | 260006237 | 1.69 | 102.3 | Curative (C) | 2019-01-21 | 2019-02-08 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 260009545 | CISPLATIN + ETOPOSIDE |
| 260009759 | 260006237 | 0 | 56 | Disease modification (D) | 2017-06-17 | 2017-06-23 | Rituximab | 2 | N | 260009545 | RITUXIMAB |
| 260009760 | 260015692 | 1.68 | 64.3 | Neo-adjuvant (N) | 2017-09-25 | 2017-10-14 | Rituximab | N | Y | 260009572 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 260009761 | 260006238 | 1.73 | 72 | Palliative (P) | 2018-12-05 | 2018-12-11 | BLEOMYCIN | 02 | N | 260009578 | NOT MATCHED |
| 260009762 | 260006239 | 0 | 91 | Disease modification (D) | 2013-10-14 | 2013-10-15 | IVE-R | 02 | Y | 260009583 | BENDAMUSTINE |
| 260009763 | 260006239 | 1.52 | 78 | Disease modification (D) | 2015-07-11 | 2015-07-15 | CARBOPLATIN + GEMCITABINE | N | N | 260009583 | CISPLATIN |
| 260009764 | 260006239 | 1.73 | null | null | 2015-03-08 | 2015-03-10 | CISPLATIN + ETOPOSIDE | 02 | null | 260009583 | NOT MATCHED |
| 260009765 | 260006239 | 1.63 | 78.6 | Palliative (P) | 2017-06-26 | 2017-06-27 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 260009583 | GEMCARBO |
| 260009766 | 260006239 | 1.8 | 107.7 | Curative (C) | 2018-12-18 | 2018-12-18 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | N | 260009583 | NOT MATCHED |
| 260009767 | 260006240 | 1.8 | 84.1 | Curative (C) | 2016-02-03 | 2016-02-04 | CISPLATIN + ETOPOSIDE | N | N | 260009670 | CISPLATIN + ETOPOSIDE |
| 260009768 | 260006240 | 1.76 | 88.6 | Palliative (P) | 2017-12-22 | 2018-01-03 | Cisplatin + Etoposide (3 day) | 2 | N | 260009670 | TRIAL |
| 260009769 | 260015694 | 1.63 | 64 | Adjuvant (A) | 2015-11-17 | 2015-11-19 | Rituximab | N | N | 260009710 | RITUXIMAB |
| 260009770 | 260006241 | null | 95 | Palliative (P) | 2018-05-17 | 2018-06-06 | Hydroxycarbamide | 02 | N | 260009736 | CARBOPLATIN + PEMETREXED |
| 260009771 | 260006242 | 1.72 | 78.8 | Palliative (P) | 2015-11-02 | 2015-11-06 | Cisplatin | N | null | 260009743 | CISPLATIN + ETOPOSIDE |
| 260009772 | 260012367 | null | 91 | Palliative (P) | null | 2014-11-06 | EP | null | null | 260009752 | CARBOPLATIN + ETOPOSIDE |
| 260009773 | 260006243 | 1.64 | null | Palliative (P) | 2018-03-22 | 2018-03-22 | FEC 100 | N | N | 260009772 | CHLORAMBUCIL + RITUXIMAB |
| 260009774 | 260006243 | 1.49 | 80.7 | Curative (C) | 2014-02-07 | 2014-02-17 | EC | N | N | 260009772 | CARBOPLATIN + ETOPOSIDE |
| 260009775 | 260006244 | 1.58 | null | null | 2016-03-28 | 2016-03-28 | BLEOMYCIN + VINCRISTINE | 2 | null | 260009791 | RITUXIMAB |
| 260009776 | 260006244 | 1.58 | 75 | Not known (9) | 2015-04-27 | 2015-04-28 | FEC 60 or 75 | N | N | 260009791 | CISPLATIN + PEMETREXED |
| 260009777 | 260006245 | null | 81.7 | Palliative (P) | 2015-03-01 | 2016-04-24 | Rituximab | N | N | 260009917 | CARBOPLATIN + ETOPOSIDE |
| 260009778 | 260006245 | 1.67 | null | Curative (C) | 2018-04-02 | 2018-04-04 | CISPLATIN + ETOPOSIDE | 02 | N | 260009917 | NOT MATCHED |
| 260009779 | 260006245 | 1.74 | null | null | null | 2016-10-02 | Cisplatin + Etoposide (3 day) | 02 | null | 260009917 | EP |
| 260009780 | 260006245 | null | 103 | Disease modification (D) | 2018-12-26 | 2019-01-09 | Trial Unspecified | N | N | 260009917 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260009781 | 260006246 | 1.8 | 79.4 | Palliative (P) | 2014-05-02 | 2014-05-04 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | N | 260009972 | EP |
| 260009782 | 260006247 | 1.75 | null | Curative (C) | 2017-10-02 | 2017-10-23 | POUT TRIAL | 02 | N | 260010008 | CISPLATIN + ETOPOSIDE |
| 260009783 | 260006247 | 1.85 | 66 | Palliative (P) | 2014-06-13 | 2014-06-24 | Cisplatin + Etoposide (5 day) | N | N | 260010008 | CISPLATIN + ETOPOSIDE |
| 260009784 | 260006248 | 1.82 | 84.6 | null | 2016-12-16 | 2016-12-24 | CVP | N | N | 260010022 | CISPLATIN + ETOPOSIDE |
| 260009785 | 260006248 | 1.77 | 87.4 | Curative (C) | null | 2019-02-16 | ETOPOSIDE | N | N | 260010022 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260009786 | 260006249 | 1.75 | 85 | Palliative (P) | 2016-07-15 | 2016-07-27 | TIP | 02 | N | 260010084 | CISPLATIN + ETOPOSIDE |
| 260009787 | 260006249 | 0 | 69.5 | Adjuvant (A) | 2015-04-06 | 2015-09-16 | Chlorambucil | N | N | 260010084 | FEC |
| 260009788 | 260006250 | 1.82 | 89.15 | Palliative (P) | null | 2016-08-01 | Doxorubicin + Olaratumab | N | N | 260010089 | CHLORAMBUCIL + OBINUTUZUMAB |
| 260009789 | 260006250 | 1.68 | 84.5 | null | 2018-05-11 | 2018-05-11 | Rituximab | 02 | null | 260010089 | FCR |
| 260009790 | 260006251 | null | 92.8 | Neo-adjuvant (N) | null | 2017-10-14 | Hydroxycarbamide | N | null | 260010109 | CYCLOPHOSPHAMIDE + DOCETAXEL |